isoxicam (BioDeep_00000180207)
human metabolite blood metabolite
代谢物信息卡片
4-hydroxy-2-methyl-N-(5-methyl-2,3-dihydro-1,2-oxazol-3-ylidene)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide
化学式: C14H13N3O5S (335.0576)
中文名称: 伊索昔康
谱图信息:
最多检出来源 Homo sapiens(blood) 100%
分子结构信息
SMILES: CC1=CC(=NO1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
InChI: InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)
描述信息
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
D018501 - Antirheumatic Agents
同义名列表
13 个代谢物同义名
4-hydroxy-2-methyl-N-(5-methyl-2,3-dihydro-1,2-oxazol-3-ylidene)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide; 4-Hydroxy-2-methyl-N-(5-methyl-3-isoxazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide; N-(5-Methyl-3-isoxazolyl)-4-hydroxy-2-methyl-2H-1,2-benzthiazine-3-carboxamide 1,1-dioxide; 4-Hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide; EINECS 252-084-5; UNII-8xu734c4NG; BRN 0577221; Isoxicamum; Isoxicamo; isoxicam; Maxicam; Vectren; W 8495
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:76163
- PubChem: 54677972
- HMDB: HMDB0253714
- DrugBank: DB08942
- ChEMBL: CHEMBL1898455
- ChEMBL: CHEMBL53292
- Wikipedia: Isoxicam
- chemspider: 10442695
- CAS: 34552-84-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Gergő Dargó, Dávid Bajusz, Kristóf Simon, Judit Müller, György T Balogh. Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Journal of medicinal chemistry.
2020 02; 63(4):1763-1774. doi:
10.1021/acs.jmedchem.0c00046. [PMID: 31995375] - David Buttar, Nicola Colclough, Stefan Gerhardt, Philip A MacFaul, Scott D Phillips, Alleyn Plowright, Paul Whittamore, Kin Tam, Klaus Maskos, Stefan Steinbacher, Holger Steuber. A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
Bioorganic & medicinal chemistry.
2010 Nov; 18(21):7486-96. doi:
10.1016/j.bmc.2010.08.052. [PMID: 20869876] - Alex Avdeef, Kin Y Tam. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?.
Journal of medicinal chemistry.
2010 May; 53(9):3566-84. doi:
10.1021/jm901846t. [PMID: 20373811] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - B Rezaei, S Mallakpour, N Majidi. Solid-phase molecularly imprinted pre-concentration and spectrophotometric determination of isoxicam in pharmaceuticals and human serum.
Talanta.
2009 Apr; 78(2):418-23. doi:
10.1016/j.talanta.2008.11.042. [PMID: 19203603] - Hye Won Lee, Hye Young Ji, Hoi Yun Kim, Kang Choon Lee, Hye Suk Lee. Liquid chromatography-tandem mass spectrometry method for the determination of meloxicam and its metabolite 5-carboxymeloxicam in human plasma.
Bioanalysis.
2009 Apr; 1(1):63-70. doi:
10.4155/bio.09.10. [PMID: 21083189] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - T F Woolf, A Black, A Sedman, T Chang. Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man.
European journal of drug metabolism and pharmacokinetics.
1992 Jan; 17(1):21-7. doi:
10.1007/bf03189983. [PMID: 1499594] - J Sassard, J Geoffroy, N Ferry, D Benzoni, M Mathieu, E Lejeune, G Llorca. Compared effects of isoxicam and indomethacin on the urinary excretion of prostaglandins in degenerative articular diseases.
Prostaglandins, leukotrienes, and essential fatty acids.
1989 Nov; 38(2):107-11. doi:
10.1016/0952-3278(89)90093-8. [PMID: 2616586] - T F Woolf, A Black, J L Hicks, H Lee, C C Huang, T Chang. In vivo metabolism of isoxicam in rats, dogs, and monkeys.
Drug metabolism and disposition: the biological fate of chemicals.
1989 Nov; 17(6):662-8. doi:
NULL. [PMID: 2575504] - F Bree, P Nguyen, E Albengres, S Urien, P Riant, P G Welling, J P Tillement. Evidence for isoxicam binding to site I as a primary site and to site II as a secondary site of human serum albumin.
Biochemical pharmacology.
1989 Mar; 38(5):753-8. doi:
10.1016/0006-2952(89)90227-x. [PMID: 2930576] - M Schmitt, T W Guentert. Effect of age on the pharmacokinetics of tenoxicam in comparison to other non-steroidal anti-inflammatory drugs (NSAIDs).
Scandinavian journal of rheumatology. Supplement.
1989; 80(?):86-9. doi:
10.3109/03009748909103719. [PMID: 2688082] - A Kinawi, D Siebler. [The binding of oxicam derivatives to human serum albumin].
Arzneimittel-Forschung.
1988 Aug; 38(8):1089-92. doi:
NULL. [PMID: 3264167] - M Tariq. Effect of some new prostaglandin synthetase inhibitors on the endotoxin induced mortality and biochemical changes in experimental animals.
Research communications in chemical pathology and pharmacology.
1988 Apr; 60(1):19-25. doi:
. [PMID: 3132734] - M Esquivel, R I Ogilvie, D S East, D H Shaw, J Heathcote. Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.
Clinical and investigative medicine. Medecine clinique et experimentale.
1987 Sep; 10(5):363-7. doi:
NULL. [PMID: 3677504] - H Fenner. Comparative biochemical pharmacology of the oxicams.
European journal of rheumatology and inflammation.
1987; 9(2):3-7. doi:
NULL. [PMID: 3447908] - H Fenner. Comparative biochemical pharmacology of the oxicams.
Scandinavian journal of rheumatology. Supplement.
1987; 65(?):97-101. doi:
10.3109/03009748709102185. [PMID: 3500509] - G Caillé, P Du Souich, L Larivière, M Vézina, Y Lacasse. The effect of administration of phenytoin on the pharmacokinetics of isoxicam.
Biopharmaceutics & drug disposition.
1987 Jan; 8(1):57-61. doi:
10.1002/bdd.2510080107. [PMID: 3580513] - E M Grace, A A Mewa, G D Sweeney, J M Rosenfeld, A C Darke, W W Buchanan. Lowering of plasma isoxicam concentrations with acetylsalicylic acid.
The Journal of rheumatology.
1986 Dec; 13(6):1119-21. doi:
NULL. [PMID: 3560102] - C F George, A G Renwick, A S Darragh, J Hosie, D Blake, W van Marle, G J Frank. A comparison of isoxicam pharmacokinetics in young and elderly subjects.
British journal of clinical pharmacology.
1986; 22 Suppl 2(?):129S-134S. doi:
10.1111/j.1365-2125.1986.tb02994.x. [PMID: 3620272] - G Caillé, L Larivière, Y Lacasse, M Vézina, J G Besner. The effect of administration of propranolol on the pharmacokinetics of isoxicam.
Biopharmaceutics & drug disposition.
1986 Jan; 7(1):63-9. doi:
10.1002/bdd.2510070109. [PMID: 3955200] - N Ferry, G Cuisinaud, D Ouzan, C Trepo, J Sassard. Pharmacokinetics of isoxicam in hepatic disease.
British journal of clinical pharmacology.
1986; 22 Suppl 2(?):143S-147S. doi:
10.1111/j.1365-2125.1986.tb02996.x. [PMID: 2887185] - P M Brooks, M McCredie, M Prowse, M Podgorski, M Forrest, I Munro, J Boutagy, L Pei-Ling. Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency.
Pharmatherapeutica.
1986; 4(10):665-72. doi:
NULL. [PMID: 3602018] - E U Kölle, K O Vollmer. Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
British journal of clinical pharmacology.
1986; 22 Suppl 2(?):135S-141S. doi:
10.1111/j.1365-2125.1986.tb02995.x. [PMID: 3620273] - J W Hooper, J A Anslow, W S Martin, P Araujo, A Darke. Fecal blood loss during isoxicam and piroxicam administration for 28 days.
Clinical pharmacology and therapeutics.
1985 Nov; 38(5):533-7. doi:
10.1038/clpt.1985.219. [PMID: 3876907] - W W Buchanan, E M Grace. Pharmacokinetics of isoxicam in the elderly.
The American journal of medicine.
1985 Oct; 79(4B):35-7. doi:
10.1016/0002-9343(85)90180-9. [PMID: 4061466] - A S Darragh. The effects of isoxicam and piroxicam on renal function in healthy subjects.
The British journal of clinical practice.
1985 Apr; 39(4):144-7. doi:
NULL. [PMID: 3940157] - R W Bury. Liquid chromatographic assay of isoxicam in human plasma and urine.
Journal of chromatography.
1985 Jan; 337(1):156-9. doi:
10.1016/0378-4347(85)80023-2. [PMID: 3980647] - R Ballerini, A Casini, M Chinol, C Mannucci, F Melani, F Ungar. Plasma and synovial fluid concentrations of isoxicam in meniscectomized patients.
Drugs under experimental and clinical research.
1985; 11(8):517-21. doi:
NULL. [PMID: 3841790] - I R Edwards, D G Ferry, A J Campbell. Factors affecting the kinetics of two benzothiazine non-steroidal anti-inflammatory medicines, piroxicam and isoxicam.
European journal of clinical pharmacology.
1985; 28(6):689-92. doi:
10.1007/bf00607917. [PMID: 4065194] - R W Bury, J A Whitworth, D Saines, P Kincaid-Smith, R F Moulds. Effect of impairment of renal function on the accumulation and disposition of isoxicam.
European journal of clinical pharmacology.
1985; 28(5):585-8. doi:
10.1007/bf00544071. [PMID: 4043201] - M Esquivel, F Cussenot, R I Ogilvie, D S East, D H Shaw. Interaction of isoxicam with acetylsalicylic acid.
British journal of clinical pharmacology.
1984 Oct; 18(4):567-71. doi:
10.1111/j.1365-2125.1984.tb02505.x. [PMID: 6487496] - B Zöller, H J Engel, G Faust-Tinnefeldt, H J Gilfrich, M Zimmer. [Interaction of isoxicam and digoxin].
Zeitschrift fur Rheumatologie.
1984 Jul; 43(4):182-4. doi:
NULL. [PMID: 6495892] - P E Borondy, B M Michniewicz. Metabolic disposition of isoxicam in man, monkey, dog, and rat.
Drug metabolism and disposition: the biological fate of chemicals.
1984 Jul; 12(4):444-51. doi:
NULL. [PMID: 6148211] - A C Daftsios, E L Johnson, F J Keeley, C Gryczko, V Rawski. High-performance liquid chromatographic analysis of isoxicam in human plasma and urine.
Journal of chromatography.
1984 Jan; 305(1):145-51. doi:
10.1016/s0378-4347(00)83322-8. [PMID: 6707138] - G DiPasquale, C Rassaert, P Welaj, J Gingold, E Schwartz. Effects of multiple treatments of isoxicam on organ weights and serum SGPT, AP, and BUN in adjuvant-induced polyarthritic rats.
Research communications in chemical pathology and pharmacology.
1978 Mar; 19(3):529-32. doi:
NULL. [PMID: 653106]
